Yıl: 2015 Cilt: 37 Sayı: 3 Sayfa Aralığı: 102 - 105 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Prognostic Significance of P53, Bcl-2, and Fas Expression in Patients with Primary Gastrointestinal Diffuse Large B-Cell Lymphoma

Öz:
Objective: P53, Bcl-2, and Fas proteins play significant roles in lymphoid cell apoptosis. These proteins affect the prognosis and treatment response of lymphoma and various malignancies. The aim of the present study was to investigate the effects of P53, Bcl-2, and Fas protein expression on treatment and prognosis in patients with primary gastrointestinal diffuse large B-cell lymphoma. Materials and Methods: Thirty-nine patients with primary gastrointestinal diffuse large B-cell lymphoma were included in the study. Immunohistochemical staining was performed to analyze P53, Bcl-2, and Fas protein expression levels in paraffin sections. Results: We examined 39 patients with primary gastrointestinal diffuse large B-cell lymphoma, 21 males and 18 females, with a median age of 54 years. P53 protein expression was detected in 24 patients (61.5%), Bcl-2 protein expression was detected in 26 (67%), and Fas protein expression was detected in 28 (72%). The five-year overall survival rate was significantly lower in patients with P53 and Bcl-2 expression; on the other hand, we did not find a significant difference in the five-year overall survival with respect to Fas protein expression. Conclusion: We found that P53 and Bcl-2 protein expression had a negative effect on prognosis and survival in patients with primary gastrointestinal diffuse large B-cell lymphoma. However, Fas protein expression had no effect on prognosis and survival. Taken together, patients with P53 and Bcl-2 expression should be considered to have a high risk from the beginning, and these patients should undergo aggressive treatments
Anahtar Kelime:

Konular: Genel ve Dahili Tıp
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Grogan TM, Jaramıllo MA, Miller TP. Natural history, diagnosis, and stagıng of the Non -Hodgkin’s Lymphomas. In: Haskell CM, Berek JS (eds). Cancer Treatment (5th ed). W.B. Saunders Company, Philedelphia, 2001, 1338-75.
  • 2. Vose JM, Chiu BC, Cheson BD. Update on Epidemiology and Therapeutics for Non-Hodgkin‘s Lymphoma. Hematology Am Soc Hematol-Educ Program 2002: 241-62. [CrossRef]
  • 3. Sarpel SC, Paydas S. Non-Hodgkin’s lymphomas in Turkey. Cancer 1988; 62(8): 1653-7. [CrossRef]
  • 4. Arıcan A, Dincol D. Clinicopathologic features and prognostic factors of primary extranodal Non-Hodgkin’s Lymphomas in Turkey. Am J Clin Oncol 1999; 22: 587-92. [CrossRef]
  • 5. Kaufmann SH, Hengartner MO. Programmed cell death: alive and well in the millennium. TRENDS in cell Biology 2001; 11(12): 526- 34. [CrossRef]
  • 6. Voutsadakis IA. Apoptosis and the Pathogenesis of Lymphoma. Acta Oncologica 2000; 39(2) :151-6. [CrossRef]
  • 7. Carson DA, Lois A. Cancer progression and p53. The Lancet 1995; 346(8981): 1009-11. [CrossRef]
  • 8. Debatin KM, Stahnke K. Apoptosis in hematological disorders. Seminars in Cancer Biology 2003; 13: 149-58. [CrossRef]
  • 9. Balıga BC, Kumar S. Role of Bcl-2 family of protems m mahgnancy. Hematological Oncology 2002; 20: 63-74. [CrossRef]
  • 10. Sartorius U, Schmitz I, Krammer PH. Molecular Mechanisms of Death- Receptor-Mediated apoptosis. Chembiochem 2001; 2: 20-9. [CrossRef]
  • 11. Saikumar P, Dong Z, Mikhailov V. Apoptosis: definition, Mechanisms and Relevance to Disease. The American Journal of Medicine 1999; 107: 489-506. [CrossRef]
  • 12. Nieder C, Petersen S, Petersen C, Thames HD. The challenge of p53 as prognostic and predictive factor in Hodgkin’s or non-Hodgkin’s lymphoma. Ann Hematol 2001; 80: 2-8. [CrossRef]
  • 13. Navaratnam S,Williams GJ, Rubinger M, Pettigrew NM, Mowat MR, Begleiter A. Expression of p53 predicts treatment failure in aggressive Non-Hodgkin’s lymphomas. Leuk Lymphoma 1998; 29(1-2): 139-44. [CrossRef]
  • 14. Hazar B, Paydas. P53 protein expression in gastrointestinal lymphomas. Oncology 1997; 54(1): 84-7. [CrossRef]
  • 15. Hermine O, Haioun C, Lepage E, dAgay MF, Briere J, Lavignac C, et al. Prognostic significance of the bcl-2 protein expression in agressive Non-Hodgkin’s lymphoma. Blood 1996; 87(1): 265-72.
  • 16. Sanchez E, Chacon I, Plaza MM, Munoz E, Cruz MA, Martinez B et al. Clinical outcome in diffuse large B-cell lymphoma is dependent on the the relationship between different cell-cycle regulator proteins. J Clin Oncol 1998; 16(5): 1931-9.
  • 17. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive Non-Hodgkin’s lymphoma. Blood 1997; 90(1): 244-51.
  • 18. Kramer MH, Hermans J, Parker J. Clinical significance of bcl-2 and p53 protein expression in diffuse large B-cell lymphoma: a population based study. J Clin Oncol 1996; 14(7): 2131-8.
  • 19. Nguyen PL, Harris NL, Ritz J Robertson MJ et al. Expression of CD95 antigen and Bcl-2 protein in Non-Hodgkin’s lymphomas and Hodgkin’s lymphomas. American Journal of Pathology 1996; 148(3): 847-53.
  • 20. Kondo E, Yoshino T, Yamadori I, Matsuo Y, Kawasaki N, Minowada J, et al. Expression of Bcl-2 protein and Fas antigen in Non-Hodgkin’s lymphomas. Am J Pathol 1994; 145(2): 330-7.
  • 21. Eser B, Sari I, Canoz O, Altuntas F, Cakmak E, Ozturk A, et al. Prognostic Significance of Fas(CD95/APO-1) Positivity in Patients with Primary Nodal Diffuse Large B-Cell Lymphoma. American Journal of Hematology 2006; 81: 307-14. [CrossRef]
  • 22. Chatzitolios A, Venizelos I, Tripsiannis G, Anastassopoulos G, Papadopoulos N. Prognostic significance of CD95, P53 and BCL2 expression in extranodal non-Hodgkin’ lymphoma. Ann Hematol 2000; 89: 889-96. [CrossRef]
  • 23. Krugmann J, Dirnhofer S, Gschwendtner A, Berresheim U, Greil R, Krugmann K, et al. Primary gastrointestinal B-cell lymphoma. A clincopathological and immunohistochemical study of 61 cases with an evaluation of prognostic parameters. Pathol Res Pract 2001; 197(6): 385-93. [CrossRef]
  • 24. Pagnano KBB, Silva MD, Vasallo J, Aranha FJ, Saad ST. Apoptosisregulating proteins and prognosis in diffuse large B cell non-Hodgkin’s lymphomas. Acta Haematol 2002; 107(1): 29-34. [CrossRef]
APA ÇAKMAK E, Sari I, canöz ö, Eser B, Altuntaş F, ÇETİN M, ÜNAL A (2015). Prognostic Significance of P53, Bcl-2, and Fas Expression in Patients with Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. , 102 - 105.
Chicago ÇAKMAK Erol,Sari Ismail,canöz özlem,Eser Bülent,Altuntaş Fevzi,ÇETİN Mustafa,ÜNAL Ali Prognostic Significance of P53, Bcl-2, and Fas Expression in Patients with Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. (2015): 102 - 105.
MLA ÇAKMAK Erol,Sari Ismail,canöz özlem,Eser Bülent,Altuntaş Fevzi,ÇETİN Mustafa,ÜNAL Ali Prognostic Significance of P53, Bcl-2, and Fas Expression in Patients with Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. , 2015, ss.102 - 105.
AMA ÇAKMAK E,Sari I,canöz ö,Eser B,Altuntaş F,ÇETİN M,ÜNAL A Prognostic Significance of P53, Bcl-2, and Fas Expression in Patients with Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. . 2015; 102 - 105.
Vancouver ÇAKMAK E,Sari I,canöz ö,Eser B,Altuntaş F,ÇETİN M,ÜNAL A Prognostic Significance of P53, Bcl-2, and Fas Expression in Patients with Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. . 2015; 102 - 105.
IEEE ÇAKMAK E,Sari I,canöz ö,Eser B,Altuntaş F,ÇETİN M,ÜNAL A "Prognostic Significance of P53, Bcl-2, and Fas Expression in Patients with Primary Gastrointestinal Diffuse Large B-Cell Lymphoma." , ss.102 - 105, 2015.
ISNAD ÇAKMAK, Erol vd. "Prognostic Significance of P53, Bcl-2, and Fas Expression in Patients with Primary Gastrointestinal Diffuse Large B-Cell Lymphoma". (2015), 102-105.
APA ÇAKMAK E, Sari I, canöz ö, Eser B, Altuntaş F, ÇETİN M, ÜNAL A (2015). Prognostic Significance of P53, Bcl-2, and Fas Expression in Patients with Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. Erciyes Medical Journal, 37(3), 102 - 105.
Chicago ÇAKMAK Erol,Sari Ismail,canöz özlem,Eser Bülent,Altuntaş Fevzi,ÇETİN Mustafa,ÜNAL Ali Prognostic Significance of P53, Bcl-2, and Fas Expression in Patients with Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. Erciyes Medical Journal 37, no.3 (2015): 102 - 105.
MLA ÇAKMAK Erol,Sari Ismail,canöz özlem,Eser Bülent,Altuntaş Fevzi,ÇETİN Mustafa,ÜNAL Ali Prognostic Significance of P53, Bcl-2, and Fas Expression in Patients with Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. Erciyes Medical Journal, vol.37, no.3, 2015, ss.102 - 105.
AMA ÇAKMAK E,Sari I,canöz ö,Eser B,Altuntaş F,ÇETİN M,ÜNAL A Prognostic Significance of P53, Bcl-2, and Fas Expression in Patients with Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. Erciyes Medical Journal. 2015; 37(3): 102 - 105.
Vancouver ÇAKMAK E,Sari I,canöz ö,Eser B,Altuntaş F,ÇETİN M,ÜNAL A Prognostic Significance of P53, Bcl-2, and Fas Expression in Patients with Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. Erciyes Medical Journal. 2015; 37(3): 102 - 105.
IEEE ÇAKMAK E,Sari I,canöz ö,Eser B,Altuntaş F,ÇETİN M,ÜNAL A "Prognostic Significance of P53, Bcl-2, and Fas Expression in Patients with Primary Gastrointestinal Diffuse Large B-Cell Lymphoma." Erciyes Medical Journal, 37, ss.102 - 105, 2015.
ISNAD ÇAKMAK, Erol vd. "Prognostic Significance of P53, Bcl-2, and Fas Expression in Patients with Primary Gastrointestinal Diffuse Large B-Cell Lymphoma". Erciyes Medical Journal 37/3 (2015), 102-105.